Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere

HIV Medicine

Volumn 13, Issue 6, 2012, Pages 352-357

  Maruszak, H ^a   Jeganathan, S ^a   Smith, D E ^a   Robertson, P ^b   Barnes, T ^a   Furner, V ^a  

^a Albion Street Centre ^*  (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

2009 pandemic; H1N1 influenza virus; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ADULT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROLOGY; SOUTHERN HEMISPHERE; TREATMENT RESPONSE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIBODIES, VIRAL; AUSTRALIA; COHORT STUDIES; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MEDICAL AUDIT; MIDDLE AGED; PANDEMICS; RETROSPECTIVE STUDIES; VACCINATION;

EID: 84862794605     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00987.x     Document Type: Article

References (23)

1. Bishop JF, Murnane MP, Owen R. Australia's winter with the 2009 pandemic influenza A (H1N1) virus. N Engl J Med 2009; 361: 2591-2594.
2. Robert Koch Institute (RKI). Notice of the Permanent Vaccination Committee of the Robert Koch-Institute for the vaccination against the novel influenza A (H1N1). Epidemiol Bull 2009; 50: 513-524.
3. CDC. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2009; 58: 1-8.
4. Nelson KE, Clements ML, Miotti P, Cohn S, Polk BF. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med 1988; 109: 383-388.
5. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000; 18: 3040-3049.
6. Cooper C, Hutton B, Fergusson D etal. A review of influenza vaccine immunogenicity and efficacy in HIV-infected adults. Can J Infect Dis Med Microbiol 2008; 19: 419-423.
7. Launay O, van der Vliet D, Rosenberg AR etal. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011; 305: 1432-1440.
8. Benne CA, Kroon FP, Harmsen M, Tavares L, Kraaijeveld CA, De Jong JC. Comparison of neutralizing haemagglutination-inhibiting antibody responses to influenza A virus vaccination of human immunodeficiency virus-infected individuals. Clin Diagn Lab Immunol 1998; 5: 114-117.
9. McClelland L, Hare R. The adsorption of influenza virus by red cells and a new in vitro method of measuring antibodies for influenza virus. Can J Public Health 1941; 32: 530.
10. European Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96). European Agency for the Evaluation of Medicinal Products, London. 1997.
11. Gilbert GL, Cretikos MA, Hueston L etal. Influenza A (H1N1) 2009 antibodies in residents of new South Wales, Australia, after the first pandemic wave in the 2009 Southern Hemisphere Winter. PLoS ONE 2010; 5: e12562.
12. Kissling E, Valenciano M, Cohen J etal. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-10: results of I-MO vaccine effectiveness multicentre case-control study. Opinions for the Control of Influenza VII, Abstract book; 2010 Sep 3-7; Hong Kong SAR, China.
13. Wichmann O, Stocker P, Poggensee G etal. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill 2010; 15: pii:19561.
14. Hardelid P, Fleming DM, McMenamin J etal. Effectiveness of pandemic and seasonal influenza vaccine in preventing influenza A (H1N1) 2009 infection in England and Scotland 2009-2010. Euro Surveill 2011; 16: pii:19763.
15. Greenberg ME, Lai MH, Hartel GF etal. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361: 2405-2413.
16. Zhu FC, Wang H, Fang HH etal. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361: 2414-2423.
17. Kajaste-Rudnitski A, Galli L, Nozza S etal. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 2011; 25: 177-183.
18. Bickel M, von Hentig N, Wieters I etal. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011; 52: 122-127.
19. Bickel M, Wieters I, Khaykin P etal. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010; 24: F31-F35.
20. Tremblay CL, Rouleau D, Fortin C etal. Immunogenicity and tolerability of inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine 2011; 29: 1359-1363.
21. Law MG, Wooley I, Templeton DJ etal. Trends in detectable viral load by calendar year in the Australian HIV observational database. J Int AIDS Soc 2011; 14: 10.
22. Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis 2008; 12: e77-e83.
23. Plana M, Garcia F, Darwich L etal. The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responses. Immunology 2011; 133: 318-328.